Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
SCYNEXIS, Inc. is a U.S.-based biopharmaceutical company focused on the discovery, development, and commercialization of novel antifungal therapies to treat serious and life-threatening invasive fungal infections. The company operates within the biotechnology and pharmaceuticals industry, with a specific emphasis on addressing unmet medical needs in infectious diseases where resistance, toxicity, or limited treatment options remain significant challenges.
The company’s primary value driver is its proprietary antifungal compound ibrexafungerp, the first in a novel class of triterpenoid antifungals, which differentiates SCYNEXIS from competitors relying on existing azole, echinocandin, or polyene drug classes. SCYNEXIS was founded in 1999 and has evolved from an early-stage discovery-focused entity into a clinical-stage and commercial-stage organization through internal research, strategic partnerships, and regulatory advancements, including U.S. Food and Drug Administration approvals.
Business Operations
SCYNEXIS generates value primarily through the development and commercialization of antifungal drug candidates. Its core operations center on ibrexafungerp, which has been approved in the United States for the treatment of vulvovaginal candidiasis (VVC) and is also being evaluated for additional indications, including invasive fungal infections. Revenue has historically been derived from collaboration agreements, milestone payments, and limited product sales following regulatory approval.
The company conducts operations primarily in the United States, with clinical development activities extending internationally through contracted clinical research organizations. SCYNEXIS maintains strategic relationships with pharmaceutical partners for development and commercialization outside the U.S., including licensing arrangements that support global clinical trials and regulatory submissions. Its asset base consists mainly of intellectual property, clinical data, and regulatory approvals rather than manufacturing infrastructure.
Strategic Position & Investments
SCYNEXIS’s strategy is centered on maximizing the clinical and commercial potential of ibrexafungerp across multiple fungal indications while exploring lifecycle management opportunities. Growth initiatives include expanding approved indications, pursuing global regulatory approvals, and leveraging partnerships to offset development costs and broaden market reach.
The company has entered into significant licensing and collaboration agreements, including arrangements with Hansoh Pharma for development and commercialization rights in Greater China. SCYNEXIS has also evaluated next-generation antifungal candidates, though its near-term strategic focus remains concentrated on advancing and commercializing its lead asset rather than building a broad pipeline through acquisitions.
Geographic Footprint
SCYNEXIS is headquartered in Jersey City, New Jersey, and its corporate operations are primarily based in the United States. Clinical development activities span North America, Europe, and parts of Asia, reflecting the global nature of antifungal disease burden and regulatory pathways.
Through licensing partnerships, the company maintains an international footprint without extensive physical infrastructure abroad. Its agreements provide indirect exposure to markets in China and other international regions, positioning SCYNEXIS to participate in global antifungal markets while remaining operationally lean.
Leadership & Governance
SCYNEXIS is led by an experienced management team with backgrounds in pharmaceuticals, infectious disease development, and public company governance. The leadership emphasizes capital discipline, regulatory execution, and strategic partnerships to advance antifungal innovation in a challenging development landscape.
Key executives include:
- David Angulo – President and Chief Executive Officer
- Stephen Gilman – Chief Financial Officer
- Shawn O’Connell – Chief Legal Officer and Corporate Secretary
- Marco Taglietti – Chief Medical Officer
The company is governed by a board of directors with experience across biotechnology, drug commercialization, and corporate finance, supporting its strategic focus on advancing differentiated antifungal therapies while managing development and market risks.